Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas.
Internal Medicine Residency Program, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Clin Gastroenterol Hepatol. 2019 Mar;17(4):784-785. doi: 10.1016/j.cgh.2018.07.010. Epub 2018 Aug 8.
Global prevalence of irritable bowel syndrome (IBS) is between 7% and 21%. Pathogenesis of IBS symptoms such as pain, altered bowel habits, and bloating is multifactorial, with central and peripheral mechanisms serving as targets for treatments. Probiotics have been studied for the treatment of IBS and are well tolerated and safe..
全球肠易激综合征（IBS）的患病率在 7%至 21%之间。IBS 症状（如疼痛、排便习惯改变和腹胀）的发病机制是多因素的，中枢和外周机制是治疗的靶点。益生菌已被用于治疗 IBS，且具有良好的耐受性和安全性。
